

CATALYST PHARMACEUTICAL PARTNERS, INC.  
Form 8-K  
May 22, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF**  
**THE SECURITIES EXCHANGE ACT OF 1934**

**May 21, 2012**

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)

*Commission File No. 001-33057*

**CATALYST PHARMACEUTICAL PARTNERS, INC.**

(Exact Name Of Registrant As Specified In Its Charter)

Delaware  
(State Or Other Jurisdiction Of  
Incorporation Or Organization)

76-0837053  
(IRS Employer  
Identification No.)

355 Alhambra Circle, Suite 1500

Coral Gables, Florida 33134

(Address Of Principal Executive Offices)  
(305) 529-2522

Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

Enrollment of Phase II(b) Clinical Trial for CPP-109

On May 21, 2012, the Company issued a press release announcing that patient enrollment in its Phase II(b) clinical trial evaluating its product candidate, CPP-109, for the treatment of cocaine addiction has been completed. A copy of the Company's press release is Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Results of Phase I(a) Clinical Trial for CPP-109

On May 22, 2012 the Company reported positive results from its Phase I(a) clinical trial evaluating the safety, tolerability and pharmacokinetics profile of CPP-115. The study demonstrated that CPP-115 was well tolerated at all six doses administered in the study.

The study was a double-blind, placebo-controlled, single ascending dose of CPP-115 solution administered orally to 55 healthy volunteers in seven cohorts of eight subjects each (one had seven subjects) with six subjects randomized to CPP-115 and two subjects randomized to placebo and with doses ranging from 5 mg to 500 mg (a dose greater than ten times the predicted effective dose based on animal models of 15-30 mg per day).

The key findings of the study included:

there were no serious or adverse events, and no cardiovascular or respiratory events were reported in the study;

CPP-115 was rapidly absorbed (time to peak blood concentration was about 30 minutes);

an elimination half-life of four to six hours; and

peak serum concentration increased in a dose proportional basis over the range of doses studied, while there was a greater than proportional increase in AUC, a method of measurement of the bioavailability of a drug based on a plot of blood concentrations sampled at frequent intervals, on the dose range.

On May 22, 2012, the Company issued a press release announcing the above-described results of the Company's Phase I(a) clinical trial for CPP-115. A copy of the Company's press release is Exhibit 99.2 to this Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press release issued by the Company on May 21, 2012

99.2 Press release issued by the Company on May 22, 2012

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Catalyst Pharmaceutical Partners, Inc.**

By: /s/ Alicia Grande  
Alicia Grande  
Vice President, Treasurer and CFO

Dated: May 22, 2012